Product
FR104
1 clinical trial
1 indication
Indication
Kidney TransplantClinical trial
A Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of FR104, a Novel Antagonist Pegylated Anti-CD28 Fab' Antibody Fragment in de Novo Renal Transplant PatientsStatus: Active (not recruiting), Estimated PCD: 2024-03-01